Nicotinic Acetylcholine Receptors and Modulation of Learning in 4- and 27-Month-Old Rabbits
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Nicotinic Stimulation Produces Multiple Forms of Increased Glutamatergic Synaptic Transmission
The Journal of Neuroscience, September 15, 1998, 18(18):7075–7083 Nicotinic Stimulation Produces Multiple Forms of Increased Glutamatergic Synaptic Transmission Kristofer A. Radcliffe and John A. Dani Division of Neuroscience, Baylor College of Medicine, Houston, Texas 77030-3498 Synaptic modulation and long-term synaptic changes are initiate calcium-dependent mechanisms that are known to in- thought to be the cellular correlates for learning and memory duce glutamatergic synaptic plasticity. The results with evoked (Madison et al., 1991; Aiba et al., 1994; Goda and Stevens, synaptic currents showed that nAChR activity can alter the 1996). The hippocampus is a center for learning and memory relationship between the incoming presynaptic activity and that receives abundant cholinergic innervation and has a high outgoing postsynaptic signaling along glutamatergic fibers. density of nicotinic acetylcholine receptors (nAChRs) (Wada et Thus, the same information arriving along the same glutama- al., 1989; Woolf, 1991). We report that strong, brief stimulation tergic afferents will be processed differently when properly of nAChRs enhanced hippocampal glutamatergic synaptic timed nicotinic activity converges onto the glutamatergic pre- transmission on two independent time scales and altered the synaptic terminals. Influencing information processing at gluta- relationship between consecutively evoked synaptic currents. matergic synapses may be one way in which nicotinic cholin- The nicotinic synaptic enhancement required extracellular cal- ergic activity influences cognitive processes. Disruption of cium and was produced by the activation of presynaptic a7- these nicotinic cholinergic mechanisms may contribute to the containing nAChRs. Although one form of glutamatergic en- deficits associated with the degeneration of cholinergic func- hancement lasted only for seconds, another form lasted for tions during Alzheimer’s disease. -
Neuronal Nicotinic Receptors: from Structure to Pathology
Progress in Neurobiology 74 (2004) 363–396 www.elsevier.com/locate/pneurobio Neuronal nicotinic receptors: from structure to pathology C. Gotti, F. Clementi* CNR, Institute of Neuroscience, Cellular and Molecular Pharmacology Section, Department of Medical Pharmacology and Center of Excellence on Neurodegenerative Diseases, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy Received 22 July 2004; accepted 29 September 2004 Available online 27 October 2004 Abstract Neuronal nicotinic receptors (NAChRs) form a heterogeneous family of ion channels that are differently expressed in many regions of the central nervous system (CNS) and peripheral nervous system. These different receptor subtypes, which have characteristic pharmacological and biophysical properties, have a pentameric structure consisting of the homomeric or heteromeric combination of 12 different subunits (a2–a10, b2–b4). By responding to the endogenous neurotransmitter acetylcholine, NAChRs contribute to a wide range of brain activities and influence a number of physiological functions. Furthermore, it is becoming evident that the perturbation of cholinergic nicotinic neurotransmission can lead to various diseases involving nAChR dysfunction during development, adulthood and ageing. In recent years, it has been discovered that NAChRs are present in a number of non-neuronal cells where they play a significant functional role and are the pathogenetic targets in several diseases. NAChRs are also the target of natural ligands and toxins including nicotine (Nic), the most widespread drug of abuse. This review will attempt to survey the major achievements reached in the study of the structure and function of NAChRs by examining their regional and cellular localisation and the molecular basis of their functional diversity mainly in pharmacological and biochemical terms. -
The Role of Serotonin in Memory: Interactions with Neurotransmitters and Downstream Signaling
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Bushehr University of Medical Sciences Repository Exp Brain Res (2014) 232:723–738 DOI 10.1007/s00221-013-3818-4 REVIEW The role of serotonin in memory: interactions with neurotransmitters and downstream signaling Mohammad Seyedabadi · Gohar Fakhfouri · Vahid Ramezani · Shahram Ejtemaei Mehr · Reza Rahimian Received: 28 April 2013 / Accepted: 20 December 2013 / Published online: 16 January 2014 © Springer-Verlag Berlin Heidelberg 2014 Abstract Serotonin, or 5-hydroxytryptamine (5-HT), is there has been an alteration in the density of serotonergic found to be involved in many physiological or pathophysi- receptors in aging and Alzheimer’s disease, and serotonin ological processes including cognitive function. Seven dis- modulators are found to alter the process of amyloidogen- tinct receptors (5-HT1–7), each with several subpopulations, esis and exert cognitive-enhancing properties. Here, we dis- have been identified for serotonin, which are different in cuss the serotonin-induced modulation of various systems terms of localization and downstream signaling. Because involved in mnesic function including cholinergic, dopa- of the development of selective agonists and antagonists minergic, GABAergic, glutamatergic transmissions as well for these receptors as well as transgenic animal models as amyloidogenesis and intracellular pathways. of cognitive disorders, our understanding of the role of serotonergic transmission in learning and memory has Keywords Serotonin · Memory · Signaling pathways improved in recent years. A large body of evidence indi- cates the interplay between serotonergic transmission and Abbreviations other neurotransmitters including acetylcholine, dopamine, 2PSDT Two-platform spatial discrimination task γ-aminobutyric acid (GABA) and glutamate, in the neu- 3xTg-AD Triple-transgenic mouse model of Alzheimer’s robiological control of learning and memory. -
Prefrontal Α7nachr Signaling Differentially Modulates Afferent
Research Articles: Systems/Circuits Prefrontal α7nAChR signaling differentially modulates afferent drive and trace fear conditioning behavior in adolescent and adult rats https://doi.org/10.1523/JNEUROSCI.1941-20.2020 Cite as: J. Neurosci 2021; 10.1523/JNEUROSCI.1941-20.2020 Received: 27 July 2020 Revised: 29 November 2020 Accepted: 23 December 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2021 the authors 1 Prefrontal α7nAChR signaling differentially modulates afferent drive 2 and trace fear conditioning behavior in adolescent and adult rats 3 4 5 6 7 Running title: Prefrontal α7nAChR control of afferent drive 8 9 10 11 Anabel M. M. Miguelez Fernandez, Hanna M. Molla, Daniel R. Thomases, and Kuei Y. Tseng* 12 13 Department of Anatomy and Cell Biology, University of Illinois at Chicago, IL 14 15 16 17 *Corresponding Author: Kuei Y. Tseng, MD, PhD 18 Department of Anatomy and Cell Biology 19 University of Illinois at Chicago – College of Medicine 20 Chicago, IL 60612, USA 21 Email: [email protected] 22 23 24 Number of figures: 8 25 Number of tables: 0 26 Abstract: 250 27 Main text: 4,030 words (Introduction: 451; Methods: 1,205; Results: 979; Discussion: 1,395) 28 29 30 31 32 Acknowledgements 33 Supported by NIH Grants R01-MH086507 and R01-MH105488 to KYT, and UIC College of Medicine 34 funds to KYT. -
Alkaloids Pp. 178-End.Pdf
Hydrastine Found in the roots and rhizomes of Hydrastis canadensis (family: Ranunculaceae). Uses: To control uterine hemorrhage. Traditional use of this root as: 1. Tonic {a medicine that strengthens). Abusamra Yousef Dr. 2. Uterine hemorrhage. 3. Catarrhal conditions. 178 Berberine: Berberies species) and)البرباريسية From Berberidaceae . .(Hydrastis)الفصيلة ال َح ْوذانية Ranunculaceae . Used as antiemetic, antibacterial and anti-inflammatory. Also, it is used for liver diseases. Sanguinarine: blood) دموية From the roots of Sanguinaria canadensis . Dr. Yousef Abusamra Yousef Dr. root) {Family Papaveraceae}. Native to America. Its effect resembles colchicine, i.e. causes doubling of chromosomes number (polyploidy). 179 . Used for atonic dyspepsia with hepatic symptoms. عسر الهضم Jatrorrhizine A protoberberine Benefits: alkaloid Antifungal, antibacterial, Antidiabetic, antiinflammatory. Dr. Yousef Abusamra Yousef Dr. Berberine 180 A quaternary amine alkaloid. Hydrastine Curare alkaloids: Bis-benzylisoquinoline. obtained from the bark and stems of Chondrodendrum tomentosum (family: Menispermaceae). The name is derived from “urari”; an Indian word indicating “poison”. The term “curare” is used to indicate the crude extract prepared from different species. Abusamra Yousef Dr. Was used by certain natives of the Amazon regions of South America as arrow poison. Some of these extracts were poisonous by virtue of a convulsant action and 181 others by paralyzing action (Most remarkable). Mechanism of action of d-tubocurarine Dr. Yousef Abusamra Yousef Dr. 182 • Curare possesses: 1. A paralyzing effect on voluntary muscles. 2. A toxic effect on blood vessels. 3. A histamine–like effect. Most of the activity is attributed to d-tubocurarine. Uses: 1- In surgical anesthesia, as it produces muscular relaxation without deep anesthesia. -
Differing Time Dependencies of Object Recognition Memory Impairments Produced by Nicotinic and Muscarinic Cholinergic Antagonism in Perirhinal Cortex
Downloaded from learnmem.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Research Differing time dependencies of object recognition memory impairments produced by nicotinic and muscarinic cholinergic antagonism in perirhinal cortex Chris J. Tinsley,1,3 Nadine S. Fontaine-Palmer,1 Maria Vincent,1 Emma P.E. Endean,1 John P. Aggleton,2 Malcolm W. Brown,1 and E. Clea Warburton1 1MRC Centre for Synaptic Plasticity, School of Physiological Sciences, Bristol University, Bristol BS8 1TD, United Kingdom; 2School of Psychology, Cardiff University, Cardiff CF10 3AT, United Kingdom The roles of muscarinic and nicotinic cholinergic receptors in perirhinal cortex in object recognition memory were com- pared. Rats’ discrimination of a novel object preference test (NOP) test was measured after either systemic or local infusion into the perirhinal cortex of the nicotinic receptor antagonist methyllycaconitine (MLA), which targets alpha-7 (a7) amongst other nicotinic receptors or the muscarinic receptor antagonists scopolamine, AFDX-384, and pirenzepine. Methyllycaconitine administered systemically or intraperirhinally before acquisition impaired recognition memory tested after a 24-h, but not a 20-min delay. In contrast, all three muscarinic antagonists produced a similar, unusual pattern of impairment with amnesia after a 20-min delay, but remembrance after a 24-h delay. Thus, the amnesic effects of nicotinic and muscarinic antagonism were doubly dissociated across the 20-min and 24-h delays. The same pattern of shorter-term but not longer-term memory impairment was found for scopolamine whether the object preference test was carried out in a square arena or a Y-maze and whether rats of the Dark Agouti or Lister-hooded strains were used. -
Neuronal Nicotinic Receptors
NEURONAL NICOTINIC RECEPTORS Dr Christopher G V Sharples and preparations lend themselves to physiological and pharmacological investigations, and there followed a Professor Susan Wonnacott period of intense study of the properties of nAChR- mediating transmission at these sites. nAChRs at the Department of Biology and Biochemistry, muscle endplate and in sympathetic ganglia could be University of Bath, Bath BA2 7AY, UK distinguished by their respective preferences for C10 and C6 polymethylene bistrimethylammonium Susan Wonnacott is Professor of compounds, notably decamethonium and Neuroscience and Christopher Sharples is a hexamethonium,5 providing the first hint of diversity post-doctoral research officer within the among nAChRs. Department of Biology and Biochemistry at Biochemical approaches to elucidate the structure the University of Bath. Their research and function of the nAChR protein in the 1970’s were focuses on understanding the molecular and facilitated by the abundance of nicotinic synapses cellular events underlying the effects of akin to the muscle endplate, in electric organs of the acute and chronic nicotinic receptor electric ray,Torpedo , and eel, Electrophorus . High stimulation. This is with the goal of affinity snakea -toxins, principallyaa -bungarotoxin ( - Bgt), enabled the nAChR protein to be purified, and elucidating the structure, function and subsequently resolved into 4 different subunits regulation of neuronal nicotinic receptors. designateda ,bg , and d .6 An additional subunit, e , was subsequently identified in adult muscle. In the early 1980’s, these subunits were cloned and sequenced, The nicotinic acetylcholine receptor (nAChR) arguably and the era of the molecular analysis of the nAChR has the longest history of experimental study of any commenced. -
Nociceptive Thresholds Are Controlled Through Spinal ОІ2-Subunit
PAINÒ 152 (2011) 2131–2137 www.elsevier.com/locate/pain Nociceptive thresholds are controlled through spinal b2-subunit-containing nicotinic acetylcholine receptors Ipek Yalcin a, Alexandre Charlet a,b, Matilde Cordero-Erausquin a, Luc-Henri Tessier a, Marina R. Picciotto c, ⇑ Rémy Schlichter a,b, Pierrick Poisbeau a,b, Marie-José Freund-Mercier a,b, Michel Barrot a, a Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Strasbourg, France b Faculté des Sciences de la Vie, Université de Strasbourg, Strasbourg, France c Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT, USA Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. article info abstract Article history: Although cholinergic drugs are known to modulate nociception, the role of endogenous acetylcholine in Received 13 October 2010 nociceptive processing remains unclear. In the current study, we evaluated the role of cholinergic trans- Received in revised form 8 April 2011 mission through spinal b2-subunit-containing nicotinic acetylcholine receptors in the control of nocicep- Accepted 8 May 2011 tive thresholds. We show that mechanical and thermal nociceptive thresholds are significantly lowered ⁄ ⁄ in b2 -knockout (KO) mice. Using nicotinic antagonists in these mice, we demonstrate that b2 -nAChRs are responsible for tonic inhibitory control of mechanical thresholds at the spinal level. We further Keywords: hypothesized that tonic b ⁄-nAChR control of mechanical nociceptive thresholds might implicate GAB- Nicotinic 2 Aergic transmission since spinal nAChR stimulation can enhance inhibitory transmission. Indeed, the b -nAChRs 2 ⁄ Acetylcholine GABAA receptor antagonist bicuculline decreased the mechanical threshold in wild-type but not b2 -KO ⁄ ⁄ GABA mice, and the agonist muscimol restored basal mechanical threshold in b2 -KO mice. -
Monoamine Oxidase Inhibitors: Promising Therapeutic Agents for Alzheimer's Disease (Review)
MOLECULAR MEDICINE REPORTS 9: 1533-1541, 2014 Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer's disease (Review) ZHIYOU CAI Department of Neurology, The Lu'an Affiliated Hospital of Anhui Medical University, Lu'an People's Hospital, Lu'an, Anhui 237005, P.R. China Received July 2, 2013; Accepted February 10, 2014 DOI: 10.3892/mmr.2014.2040 Abstract. Activated monoamine oxidase (MAO) has a critical 6. MAO activation contributes to cognitive impairment in role in the pathogenesis of Alzheimer's disease (AD), including patients with AD the formation of amyloid plaques from amyloid β peptide (Aβ) 7. Activated MAO contributes to the formation of amyloid production and accumulation, formation of neurofibrillary plaques tangles, and cognitive impairment via the destruction of cholin- 8. Is activated MAO associated with the formation of ergic neurons and disorder of the cholinergic system. Several neurofibrillary tangles? studies have indicated that MAO inhibitors improve cognitive 9. Evidence for the neuroprotective effect of MAO inhibitors deficits and reverse Aβ pathology by modulating proteolytic in AD cleavage of amyloid precursor protein and decreasing Aβ 10. Conclusions and outlook protein fragments. Thus, MAO inhibitors may be considered as promising therapeutic agents for AD. 1. Introduction Monoamine oxidase (MAO) catalyzes the oxidative deamina- Contents tion of biogenic and xenobiotic amines and has an important role in the metabolism of neuroactive and vasoactive amines in 1. Introduction the central nervous system (CNS) and peripheral tissues. The 2. Monoamine oxidase (MAO) enzyme preferentially degrades benzylamine and phenylethyl- 3. Involvement of MAO in neurodegeneration amine and targets a wide variety of specific neurotransmitters 4. -
Early Life Stress, Nicotinic Acetylcholine Receptors and Alcohol Use Disorders
Brain Sci. 2015, 5, 258-274; doi:10.3390/brainsci5030258 OPEN ACCESS brain sciences ISSN 2076-3425 www.mdpi.com/journal/brainsci/ Review Early Life Stress, Nicotinic Acetylcholine Receptors and Alcohol Use Disorders Joan Y. Holgate * and Selena E. Bartlett Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, 37 Kent St, Woolloongabba, Queensland 4102, Australia; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +61-7-3443-7285; Fax: +61-7-3443-7779. Academic Editor: Marcelo Febo Received: 15 April 2015 / Accepted: 18 June 2015 / Published: 30 June 2015 Abstract: Stress is a major driving force in alcohol use disorders (AUDs). It influences how much one consumes, craving intensity and whether an abstinent individual will return to harmful alcohol consumption. We are most vulnerable to the effects of stress during early development, and exposure to multiple traumatic early life events dramatically increases the risk for AUDs. However, not everyone exposed to early life stress will develop an AUD. The mechanisms determining whether an individual’s brain adapts and becomes resilient to the effects of stress or succumbs and is unable to cope with stress remain elusive. Emerging evidence suggests that neuroplastic changes in the nucleus accumbens (NAc) following early life stress underlie the development of AUDs. This review discusses the impact of early life stress on NAc structure and function, how these changes affect cholinergic signaling within the mesolimbic reward pathway and the role nicotinic acetylcholine receptors (nAChRs) play in this process. -
The Pharmacologist 2 0 0 8 March
Vol. 50 Number 1 The Pharmacologist 2 0 0 8 March Happy Birthday ASPET!!! th 100 Anniversary Celebration Details Inside: Don’t Miss the ASPET Centennial Meeting At Experimental Biology 2008 April 5-9, 2008, San Diego Featuring: Exciting Opening Reception: DJ, Food, Drinks and more Special Centennial Symposia: Exciting topics from each division Centennial Store: Selling ASPET merchandise for the first time ever ASPET Birthday Party: A Street Festival in the Gaslamp District ASPET Student Fiesta: Band, Food, and Drinks Nobel Laureate Reception: For Students to meet Nobel Laureates Great Giveaways: Luggage Tags, Pins, Posters, Compendiums Abel Number Lounge: Look up your Abel Number Plus Much More!! Also Inside this Issue: ASPET Election Results ASPET Award Winners 2008 EB 2008 Program Grid Special Executive Officer Interview Abstracts from the Great Lakes Chapter and Southeastern Chapter Meetings A Publication of the American Society for 1 Pharmacology and Experimental Therapeutics - ASPET Volume 50 Number 1, 2008 The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. The PHARMACOLOGIST Editor Suzie Thompson EDITORIAL ADVISORY BOARD News Bryan F. Cox, Ph.D. Ronald N. Hines, Ph.D. Terrence J. Monks, Ph.D. Election Results . page 3 COUNCIL Award Winners for 2008. page 4 President Kenneth P. Minneman, Ph.D. EB 2008 Program Grid . page 12 President-Elect ASPET Centennial Update . page 17 Joe A. Beavo, Ph.D. Past President Special Centennial Feature: The View From the Elaine Sanders-Bush, Ph.D. Executive Office . page 21 Secretary/Treasurer Annette E. Fleckenstein, Ph.D. Special Lecture: The Origin and Development of Secretary/Treasurer-Elect Behavioral Pharmacology . -
Alzheimer Dementia: Starting, Stopping Drug Therapy
REVIEW CME CREDIT LUKE D. KIM, MD, FACP, CMD RONAN M. FACTORA, MD, FACP, AGSF Assistant Professor of Medicine, Cleveland Clinic Lerner Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, College of Medicine of Case Western Reserve University, Cleveland, OH; Center for Geriatric Medicine, Medicine Cleveland, OH; Center for Geriatric Medicine, Medicine Institute, Cleveland Clinic Institute, Cleveland Clinic Alzheimer dementia: Starting, stopping drug therapy ABSTRACT lzheimer disease is the most common A form of dementia. In 2016, an estimated Alzheimer disease is the most common type of dementia. 5.2 million Americans age 65 and older had Two classes of cognition-enhancing drugs are approved Alzheimer disease. The prevalence is project- to treat the symptoms, and both have provided modest ed to increase to 13.8 million by 2050, includ- benefi t in clinical trials. Psychotropic drugs are sometimes ing 7 million people age 85 and older.1 used off-label to treat behavioral symptoms of Alzheimer Although no cure for dementia exists, sev- disease. All these medications should be continuously eral cognition-enhancing drugs have been ap- evaluated for clinical effi cacy and, when appropriate, proved by the US Food and Drug Administra- discontinued if the primary benefi t—preservation of cog- tion (FDA) to treat the symptoms of Alzheimer nitive and functional status and a reduction in behaviors dementia. The purpose of these drugs is to associated with dementia—is no longer being achieved. stabilize cognitive and functional status, with a secondary benefi t of potentially reducing be- KEY POINTS havioral problems associated with dementia.